Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Deanna Kornacki"'
Autor:
Ignace Vergote, Frédéric Selle, Dominique Berton-Rigaud, Patricia Pautier, Chuan Tian, Anna Kryzhanivska, Antoine Angelergues, Deanna Kornacki, Monika Dudzisz-Sledz, Nawel Bourayou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/b5f7b08381ed40d3a54acbd8310118b9
Autor:
Srdan Verstovsek, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, Carole B. Miller, Richard T. Silver, Moshe Talpaz, Elliott F. Winton, Jimmie H. Harvey, Murat O. Arcasoy, Elizabeth O. Hexner, Roger M. Lyons, Ronald Paquette, Azra Raza, Mark Jones, Deanna Kornacki, Kang Sun, Hagop Kantarjian, for the COMFORT-I investigators
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2017)
Abstract Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I
Externí odkaz:
https://doaj.org/article/7414efd9cbe24affac81f3167f71f9d0
Autor:
Deanna Kornacki, Moshe Talpaz, Josef T. Prchal, Jason Clark, Srdan Verstovsek, Solomon I. Hamburg, Philomena Colucci, Murat O. Arcasoy, Lawrence B. Afrin
Publikováno v:
Clinical lymphoma, myeloma & leukemia, vol 22, iss 5
Introduction : Treatment options in patients with myelofibrosis (MF) presenting with thrombocytopenia are limited. Final results of the phase 2 study (NCT01348490) of ruxolitinib in patients with MF and low baseline platelet counts (50–100 × 109/L
Autor:
Julien Seneschal, Albert Wolkerstorfer, Seemal R Desai, Pearl Grimes, Khaled Ezzedine, Deanna Kornacki, Shaoceng Wei, Kathleen Butler, David Rosmarin
Publikováno v:
British Journal of Dermatology. 188
Vitiligo is a chronic autoimmune disease that targets melanocytes, causing skin depigmentation. Disease pathogenesis is largely regulated by interferon-γ activation of the Janus kinase (JAK) signalling pathway. A cream formulation of the JAK1/JAK2 i
Autor:
Thierry Passeron, John E Harris, Amit G Pandya, Julien Seneschal, Pearl Grimes, Deanna Kornacki, Mingyue Wang, Kathleen Butler, Khaled Ezzedine, David Rosmarin
Publikováno v:
British Journal of Dermatology. 188
Vitiligo is a chronic inflammatory autoimmune disease that targets melanocytes, causing skin de-pigmentation. A cream formulation of the Janus kinase (JAK) 1/JAK2 inhibitor, ruxolitinib demonstrated substantial re-pigmentation in a phase 2 study in a
Autor:
David, Rosmarin, Thierry, Passeron, Amit G, Pandya, Pearl, Grimes, John E, Harris, Seemal R, Desai, Mark, Lebwohl, Mireille, Ruer-Mulard, Julien, Seneschal, Albert, Wolkerstorfer, Deanna, Kornacki, Kang, Sun, Kathleen, Butler, Khaled, Ezzedine, Jonathan, Wolfe
Publikováno v:
TRuE-V Study Group 2022, ' Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo ', New England Journal of Medicine, vol. 387, no. 16, pp. 1445-1455 . https://doi.org/10.1056/NEJMoa2118828
New England Journal of Medicine, 387(16), 1445-1455. Massachussetts Medical Society
The New England journal of medicine, 387(16), 1445-1455. Massachussetts Medical Society
New England Journal of Medicine, 387(16), 1445-1455. Massachussetts Medical Society
The New England journal of medicine, 387(16), 1445-1455. Massachussetts Medical Society
BACKGROUND: Vitiligo is a chronic autoimmune disease that causes skin depigmentation. A cream formulation of ruxolitinib (an inhibitor of Janus kinase 1 and 2) resulted in repigmentation in a phase 2 trial involving adults with vitiligo. METHODS: We
Publikováno v:
Journal of the American Academy of Dermatology. 82:412-419
Background There are currently no treatments for alopecia areata (AA) that are universally effective or approved by the US Food and Drug Administration. Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid sy
Autor:
Moshe, Talpaz, Josef, Prchal, Lawrence, Afrin, Murat, Arcasoy, Solomon, Hamburg, Jason, Clark, Deanna, Kornacki, Philomena, Colucci, Srdan, Verstovsek
Publikováno v:
Clinical lymphoma, myelomaleukemia. 22(5)
Treatment options in patients with myelofibrosis (MF) presenting with thrombocytopenia are limited. Final results of the phase 2 study (NCT01348490) of ruxolitinib in patients with MF and low baseline platelet counts (50 - 100 × 10Patients received
Autor:
Ruben A. Mesa, John F. DiPersio, Richard T. Silver, Kang Sun, Elliott F. Winton, Jason Gotlib, Hagop M. Kantarjian, Comfort-I investigators, Elizabeth O. Hexner, Srdan Verstovsek, John Catalano, Moshe Talpaz, Jimmie H. Harvey, Murat O. Arcasoy, Carole B. Miller, Roger M. Lyons, Deanna Kornacki, Vikas Gupta, Azra Raza, Ronald Paquette, Michael W. Deininger
Publikováno v:
Journal of Clinical Oncology. 34:7012-7012
7012Background: The JAK1/JAK2 inhibitor RUX has demonstrated rapid and durable improvements in splenomegaly and symptoms and improved survival in the phase 3 COMFORT studies in pts with MF. Here we...